2025년
한국질량분석학회 여름학술대회 및 총회
2025. 08.27 (수) ~ 2025. 08.29 (금)
부산항국제전시컨벤션센터(BPEX)
초록검색
| 제목 | Advanced Characterization of Semaglutide and Its Impurities Using a Heart-Cutting 2D-LC/MS Workflow for Biopharmaceutical Analysis |
|---|---|
| 작성자 | 김슬기 (한국애질런트테크놀로지스) |
| 발표구분 | 포스터발표 |
| 발표분야 | 4. Medical / Pharmaceutical Science |
| 발표자 |
Ju Hwan Lim (Agilent Technologies Korea) |
| 주저자 | Ju Hwan Lim (Agilent Technologies Korea) |
| 교신저자 |
Ju Hwan Lim (Agilent Technologies Korea) |
| 저자 |
Ju Hwan Lim (Agilent Technologies Korea) Tanya Jones (Agilent Technologies, Inc. Raleigh, NC) Paramjeet Khandpur (Agilent Technologies, Inc. Bengaluru, India) Ashish Pargaonkar (Agilent Technologies, Inc. Bengaluru, India) Preeti Bharatiya (Agilent Technologies, Inc. Bengaluru, India) |
|
Synthetic peptides are widely used in therapeutics for their high potency and specificity. However, their structural diversity makes impurity profiling critical, especially during GMP manufacturing, where impurities from deletions, insertions, or degradation can affect safety and efficacy. GLP-1 receptor agonists like semaglutide (MW 4,113.58 Da) are prominent in treating type II diabetes and obesity. Related variants often coelute with the main peak, making their detection challenging in conventional LC/MS workflows. A 2D-LC/MS workflow was implemented using the Agilent 1290 Infinity III Bio 2D-LC system with multiple heart-cutting, coupled to the 6545XT AdvanceBio LC/Q-TOF and BioConfirm software. The phosphate-buffer-based 1D separation offers high resolution, while the 2D step enables MS-compatible desalting and improved impurity detection.
|
|